FindTrial
Sign In

PROBENECID IN MEN WITH ASTHENOZOOSPERMIA

ROLE OF PROBENACID IN IMPROVING PROGRESSIVE MOTILITY IN INFERTILE MEN WITH ASTHENOSPERMIA: A PROSPECTIVE COHORT STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052827
Enrollment
200
Registered
2023-05-18
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N468- Other male infertility

Interventions

Intervention1: Probenecid: Probenecid given orally, 250 mg, twice a day for 1 week followed by 500mg twice a day for 11 weeks. Semen analysis is done before starting the drug and after 12 weeks of tre

Sponsors

Dr Tejas Gundewar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Infertile men with idiopathic asthenozoospermia on semen analysis. 2. Couples where female factor infertility has been ruled out.

Exclusion criteria

Exclusion criteria: Azoospermia. 2. Not willing to participate. 3. Varicocele. 4. Couples with female factor infertility 5. Diabetes 6. Epididymitis, orchitis and leucocytospermia.

Design outcomes

Primary

MeasureTime frame
To study the effect of probenecid on rapid progressive sperm motility in infertile men with asthenospermia.Timepoint: Baseline and 12 weeks—

Secondary

MeasureTime frame
To study the effect of probenecid on slow progressive motility. 2. To study the effect of probenecid on sperm count. 3. To study the effect of probenecid on sperm morphology. 4. To study the pregnancy rates after treatment with probenecid.Timepoint: Baseline and 12 weeks—

Countries

India

Contacts

Public ContactTejas Gundewar

Chief male and female infertility consultant, Ruby Hall Clinic, 40 -sassoon road, Pune

tejasgundewar87@gmail.com9970054337

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026